These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38250842)

  • 1. Latent Class Analysis Identifies Distinct Phenotypes of Systemic Lupus Erythematosus Predictive of Flares after mRNA COVID-19 Vaccination: Results from the Coronavirus National Vaccine Registry for ImmuNe Diseases SINGapore (CONVIN-SING).
    Sim TM; Lahiri M; Ma M; Cheung PP; Mak A; Fong W; Angkodjojo S; Xu C; Kong KO; Arkachaisri T; Phang KF; Tan TC; Yap QV; Chan YH; Sriranganathan M; Chuah TY; Roslan NE; Poh YJ; Law A; Santosa A; Tay SH
    Vaccines (Basel); 2023 Dec; 12(1):. PubMed ID: 38250842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-mRNA vaccine flares in autoimmune inflammatory rheumatic diseases: Results from the COronavirus National Vaccine registry for ImmuNe diseases SINGapore (CONVIN-SING).
    Ma M; Santosa A; Fong W; Chew LC; Low AH; Law A; Poh YJ; Yeo SI; Leung YY; Ng VW; Koh JZ; Tay SH; Mak A; Teng GG; Xu C; Tang JG; Kong KO; Angkodjojo S; Goh WR; Chuah TY; Roslan NE; Arkachaisri T; Teh KL; Sriranganathan M; Tan TC; Phang KF; Yap QV; Chan YH; Cheung PP; Lahiri M
    J Autoimmun; 2023 Jan; 134():102959. PubMed ID: 36473406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hesitancy for SARS-CoV-2 vaccines and post-vaccination flares in patients with systemic lupus erythematosus.
    Mok CC; Chan KL; Tse SM
    Vaccine; 2022 Sep; 40(41):5959-5964. PubMed ID: 36085256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of disease flares after SARS-CoV-2 mRNA vaccination in patients with systemic lupus erythematosus.
    Kikuchi J; Kondo Y; Kojima S; Kasai S; Sakai Y; Takeshita M; Hiramoto K; Saito S; Fukui H; Hanaoka H; Suzuki K; Kaneko Y
    Immunol Med; 2024 Jun; 47(2):76-84. PubMed ID: 38189429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus.
    Yoshida T; Tsuji H; Onishi A; Takase Y; Shirakashi M; Onizawa H; Hiwa R; Kitagori K; Akizuki S; Nakashima R; Tanaka M; Yoshifuji H; Morinobu A
    Lupus Sci Med; 2022 Aug; 9(1):. PubMed ID: 35961691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS-CoV-2 Vaccination.
    Izmirly PM; Kim MY; Samanovic M; Fernandez-Ruiz R; Ohana S; Deonaraine KK; Engel AJ; Masson M; Xie X; Cornelius AR; Herati RS; Haberman RH; Scher JU; Guttmann A; Blank RB; Plotz B; Haj-Ali M; Banbury B; Stream S; Hasan G; Ho G; Rackoff P; Blazer AD; Tseng CE; Belmont HM; Saxena A; Mulligan MJ; Clancy RM; Buyon JP
    Arthritis Rheumatol; 2022 Feb; 74(2):284-294. PubMed ID: 34347939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study.
    Cho J; Shen L; Huq M; Kandane-Rathnayake R; Golder V; Louthrenoo W; Chen YH; Hamijoyo L; Luo SF; Wu YJ; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake D; Chan M; Kikuchi J; Takeuchi T; Bae SC; Oon S; O'Neill S; Goldblatt F; Ng KPL; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Navarra SV; Lau CS; Hoi A; Morand EF; Nikpour M; Lateef A;
    Lancet Rheumatol; 2023 Oct; 5(10):e584-e593. PubMed ID: 38251484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short- and mid-term outcomes in systemic lupus erythematosus patients presenting with disease exacerbation after SARS-CoV-2 mRNA vaccination: A cohort study from Puerto Rico.
    González-Meléndez A; Báez-Negrón L; Ríos-Rivera R; Franco-O'Connell AS; Nieves-Plaza M; Vilá LM
    Lupus; 2023 Apr; 32(4):571-579. PubMed ID: 36639887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of a weak antibody response to COVID-19 mRNA vaccine in systemic lupus erythematosus.
    Parsons C; Rubio J; Boulougoura A; Krishfield S; Kyttaris V
    Rheumatol Int; 2023 Sep; 43(9):1621-1627. PubMed ID: 37310438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoimmune Rheumatic Disease Flares with Myocarditis Following COVID-19 mRNA Vaccination: A Case-Based Review.
    Lai YW; Chua CG; Lim XR; Francis PJ; Xu C; Howe HS
    Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Systemic Lupus Erythematosus and Immunosuppressive Agents on COVID-19 Vaccination Antibody Response.
    Petri M; Joyce D; Haag K; Fava A; Goldman DW; Zhong D; Xiao S; Milstone A; Magder LS
    Arthritis Care Res (Hoboken); 2023 Sep; 75(9):1878-1885. PubMed ID: 36714913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asthma phenotypes in a multi-ethnic Asian cohort.
    Tay TR; Choo XN; Yii A; Chung KF; Chan YH; Wong HS; Chan A; Tee A; Koh MS
    Respir Med; 2019 Oct; 157():42-48. PubMed ID: 31499296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost of flares among patients with systemic lupus erythematosus with and without lupus nephritis in the United States.
    Bell CF; Huang SP; Cyhaniuk A; Averell CM
    Lupus; 2023 Feb; 32(2):301-309. PubMed ID: 36542670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and factors associated with flares following COVID-19 mRNA vaccination in patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: a national cohort study.
    Fong W; Woon TH; Chew LC; Low A; Law A; Poh YJ; Yeo SI; Leung YY; Ma M; Santosa A; Kong KO; Xu C; Teng GG; Mak A; Tay SH; Chuah TY; Roslan NE; Angkodjojo S; Phang KF; Sriranganathan M; Tan TC; Cheung P; Lahiri M
    Adv Rheumatol; 2023 Aug; 63(1):38. PubMed ID: 37528453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting flares in patients with stable systemic lupus erythematosus.
    Cho J; Lahiri M; Teoh LK; Dhanasekaran P; Cheung PP; Lateef A
    Semin Arthritis Rheum; 2019 Aug; 49(1):91-97. PubMed ID: 30660381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey.
    Rider LG; Parks CG; Wilkerson J; Schiffenbauer AI; Kwok RK; Noroozi Farhadi P; Nazir S; Ritter R; Sirotich E; Kennedy K; Larche MJ; Levine M; Sattui SE; Liew JW; Harrison CO; Moni TT; Miller AK; Putman M; Hausmann J; Simard JF; Sparks JA; Miller FW;
    Rheumatology (Oxford); 2022 Jun; 61(SI2):SI143-SI150. PubMed ID: 35460240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interventions for cutaneous disease in systemic lupus erythematosus.
    Hannon CW; McCourt C; Lima HC; Chen S; Bennett C
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD007478. PubMed ID: 33687069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Appraising SARS-CoV-2 infections after full mRNA COVID-19 vaccination in patients with systemic lupus erythematosus (SLE).
    Anuforo A; Sandhu M; Yu J; Perl A
    Clin Immunol Commun; 2022 Dec; 2():54-56. PubMed ID: 38620676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of flare in SLE patients fulfilling lupus low disease activity state: a cohort study of 292 patients with 36-month follow-up.
    Cunha RN; Saraiva L; Jesus D; Doria A; da Silva JP; Inês LS
    Rheumatology (Oxford); 2023 Nov; 62(11):3627-3635. PubMed ID: 36847423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attitudes towards and safety of the SARS-CoV-2 inactivated vaccines in 188 patients with systemic lupus erythematosus: a post-vaccination cross-sectional survey.
    Tang Q; Li F; Tian J; Kang J; He J
    Clin Exp Med; 2023 Jun; 23(2):457-463. PubMed ID: 35612692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.